<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01322854</url>
  </required_header>
  <id_info>
    <org_study_id>IMRT-MC2</org_study_id>
    <nct_id>NCT01322854</nct_id>
  </id_info>
  <brief_title>Adjuvant Whole Breast Radiotherapy (RT) With Intensity Modulated Radiotherapy (IMRT) and a Simultaneous Integrated Boost Versus Conventional RT and a Sequential Boost</brief_title>
  <acronym>IMRT-MC2</acronym>
  <official_title>Randomized Phase III Trial Comparing Intensity Modulated Radiotherapy With Integrated Boost to Conventional Radiotherapy With Consecutive Boost in Patients With Breast Cancer After Breast Conserving Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DLR German Aerospace Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The IMRT-MC2 study is a prospective, two armed, multicenter, randomized phase-III-trial
      comparing intensity modulated radiotherapy with integrated boost to conventional radiotherapy
      with consecutive boost in patients with breast cancer after breast conserving surgery. 502
      patients will be recruited and randomized in two arms: patients in arm A will receive IMRT in
      28 fractions delivering 50.4 Gy to the breast and 64.4 Gy to the tumor-bed by an integrated
      boost, while patients in arm B will receive conventional radiotherapy of the breast in 28
      fractions to a dose of 50.4 Gy and a consecutive boost in 8 fractions to a total dose of 66.4
      Gy. Primary aim of the study is the assessment of the cosmetic outcome and local control
      after breast radiotherapy. The study hypothesis is that intensity modulated radiotherapy
      (IMRT) is, in spite of the reduced treatment duration, at least equivalent to conventional
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cosmetic results</measure>
    <time_frame>2 years</time_frame>
    <description>The cosmetic outcome will be assessed by two independent investigators using the Harvard criteria (excellent, good, fair, poor). Additional parameters to be evaluated are skin color, teleangiectasy, scars, shrinking and asymmetry. Evaluation will also be carried out using a quantitative digitizer scoring system based on standardized photodocumentations of the breast, as described by Vrieling et al.. by calculation of a breast retraction assessment (BRA) score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>local recurrence rates</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fraction of patients surviving (overall survival)</measure>
    <time_frame>15 years</time_frame>
    <description>ratio of number of patients alive to total number of patients treated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fraction of patients surviving without tumor recurrence (disease-free survival)</measure>
    <time_frame>15 years</time_frame>
    <description>ratio of patients alive without tumor recurrence to total number of patients treated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>EORTC questionnaires QLQ-C30 and QLQ-BR23</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurence of secondary malignancies</measure>
    <time_frame>15 years</time_frame>
    <description>ratio of patients with occurence of secondary malignancies to total number of patients treated</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">502</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>IMRT + integrated boost</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed by an integrated boost</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional RT + sequential boost</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Conventional radiotherapy of the whole breast in 28 fractions to a dose of 50.4 Gy and a consecutive boost in 8 fractions to a total dose of 66.4 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>IMRT with an simultaneous integrated boost</intervention_name>
    <description>IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed</description>
    <arm_group_label>IMRT + integrated boost</arm_group_label>
    <arm_group_label>Conventional RT + sequential boost</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients aged &gt;18 years and &lt; 70 years after breast conserving surgery.

          -  Patients aged ≥ 70 years with following risk factors:

               -  Tumor stadium ≥ T2

               -  Multifocal disease

               -  Lymphangiosis

               -  Extended intraductal component

               -  Resection margin ≤3mm

        Exclusion Criteria:

          -  Refusal of the patients to be included in the study

          -  Karnofsky Performance Score ≤ 70%

          -  Metastatic disease (M1)

          -  Other malignancies

          -  Previous radiotherapy of the breast

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juergen Debus, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heidelberg University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Holger Hof, MD</last_name>
    <phone>+496221568202</phone>
    <email>holger.hof@med.uni-heidelberg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vasileios Askoxylakis, MD</last_name>
    <phone>+496221568202</phone>
    <email>vasileios.askoxylakis@med.uni-heidelberg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Heidelberg, Dept. Radiation Oncology</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Holger Hof, MD</last_name>
      <phone>+496221568202</phone>
      <email>holger.hof@med.uni-heidelberg.de</email>
    </contact>
    <contact_backup>
      <last_name>Vasileios Askoxylakis, MD</last_name>
      <phone>+496221568202</phone>
      <email>vasileios.askoxylakis@med.uni-heidelberg.de</email>
    </contact_backup>
    <investigator>
      <last_name>Holger Hof, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juergen Debus, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vasileios Askoxylakis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonie Fetzner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Haefner, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jörg Heil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexandra Jensen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Heidelberg, Dept. Radiation Oncology</name>
      <address>
        <city>Mannheim</city>
        <zip>68135</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Frederik Wenz, MD</last_name>
      <phone>+496213833530</phone>
      <email>frederik.wenz@medma.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Frederik Wenz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2011</study_first_submitted>
  <study_first_submitted_qc>March 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2011</study_first_posted>
  <last_update_submitted>April 6, 2011</last_update_submitted>
  <last_update_submitted_qc>April 6, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Juergen Debus, Prof. Dr. Dr.</name_title>
    <organization>University of Heidelberg</organization>
  </responsible_party>
  <keyword>IMRT</keyword>
  <keyword>Integrated boost</keyword>
  <keyword>adjuvant radiotherapy</keyword>
  <keyword>breast cancer</keyword>
  <keyword>breast conserving surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

